Trump takes back $11 billion in public health funding

31 March 2025

The US government is reclaiming over $11 billion in unspent public health funds originally allocated during the COVID-19 emergency, a move that has drawn sharp criticism from lawmakers and public health advocates who warn it will weaken the country’s ability to respond to future health threats and disrupt essential care services.

Rosa DeLauro, a senior Democrat on the House Appropriations Committee, accused former President Donald Trump and entrepreneur Elon Musk of driving the decision, saying they are “stealing funds promised to Americans for substance abuse treatment and mental health services.” She warned that states will be forced to cancel contracts for addiction counseling and behavioral health services, with job losses expected across frontline roles.

The funds being pulled include roughly $11.4 billion from the Centers for Disease Control and Prevention and around $1 billion from the Substance Abuse and Mental Health Services Administration. Many of these grants had been expected to continue through September 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical